|
US5476659A
(en)
*
|
1982-11-09 |
1995-12-19 |
The Scripps Research Institute |
Cancerous B cell treatment using substituted nucleoside derivatives
|
|
US5851526A
(en)
*
|
1985-04-19 |
1998-12-22 |
Ludwig Institute For Cancer Research |
Methods of treating colon cancer utilizing tumor-specific antibodies
|
|
US5776093A
(en)
*
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
|
CA2085586A1
(en)
*
|
1990-06-22 |
1991-12-23 |
Timothy J. Gorzynski |
Ascites production of monoclonal antibodies using an immunosuppressive anti-cd4-related antibody
|
|
US5277892A
(en)
*
|
1990-08-08 |
1994-01-11 |
Rhomed Incorporated |
In vivo lymphocyte tagging
|
|
US6329509B1
(en)
*
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
|
US5994514A
(en)
*
|
1991-08-14 |
1999-11-30 |
Genentech, Inc. |
Immunoglobulin variants
|
|
US6685939B2
(en)
|
1991-08-14 |
2004-02-03 |
Genentech, Inc. |
Method of preventing the onset of allergic disorders
|
|
US5965709A
(en)
*
|
1991-08-14 |
1999-10-12 |
Genentech, Inc. |
IgE antagonists
|
|
US5643549A
(en)
*
|
1992-02-20 |
1997-07-01 |
Rhomed Incorporated |
Leukostimulatory agent for in vivo leukocyte tagging
|
|
AU5845594A
(en)
*
|
1992-11-13 |
1994-06-08 |
Scripps Research Institute, The |
Cancerous b cell treatment using substituted nucleoside derivatives
|
|
AU5958494A
(en)
*
|
1992-12-21 |
1994-07-19 |
Tanox Biosystems, Inc. |
Allergen-specific iga monoclonal antibodies and related products for allergy treatment
|
|
US20030133955A1
(en)
*
|
1993-02-22 |
2003-07-17 |
American Bioscience, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US20030068362A1
(en)
*
|
1993-02-22 |
2003-04-10 |
American Bioscience, Inc. |
Methods and formulations for the delivery of pharmacologically active agents
|
|
US20070116761A1
(en)
*
|
1993-02-22 |
2007-05-24 |
Desai Neil P |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
US20030073642A1
(en)
*
|
1993-02-22 |
2003-04-17 |
American Bioscience, Inc. |
Methods and formulations for delivery of pharmacologically active agents
|
|
WO1994018954A1
(en)
*
|
1993-02-22 |
1994-09-01 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of biologics and compositions useful therefor
|
|
US5800991A
(en)
*
|
1994-03-11 |
1998-09-01 |
University Of Kentucky Research Foundation |
Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics
|
|
US5596081A
(en)
*
|
1994-03-11 |
1997-01-21 |
University Of Kentucky Research Foundation |
Nucleotide or nucleoside photoaffinity compound modified antibodies, methods for their manufacture and use thereof as diagnostics and therapeutics
|
|
US6037453A
(en)
*
|
1995-03-15 |
2000-03-14 |
Genentech, Inc. |
Immunoglobulin variants
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US20040197326A1
(en)
*
|
1995-07-27 |
2004-10-07 |
Genentech, Inc. |
Method for treatment of allergic asthma
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
NZ502500A
(en)
*
|
1997-06-27 |
2002-03-28 |
Vivorx Pharmaceuticals Inc |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
|
MY133346A
(en)
*
|
1999-03-01 |
2007-11-30 |
Biogen Inc |
Kit for radiolabeling ligands with yttrium-90
|
|
US20020102208A1
(en)
*
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
|
EP1637160A3
(de)
*
|
1999-05-07 |
2006-05-03 |
Genentech, Inc. |
Behandlung von Autoimmunkrankheiten mit Antagonisten die Oberflächenmarker von B Zellen binden
|
|
US7829064B2
(en)
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
US8383081B2
(en)
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
US8119101B2
(en)
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
|
HK1046635B
(en)
|
1999-06-09 |
2009-10-09 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
KR20080075044A
(ko)
*
|
1999-07-12 |
2008-08-13 |
제넨테크, 인크. |
Cd20에 결합하는 길항제를 사용한 외래 항원에 대한 면역반응 차단 방법
|
|
CN104383535A
(zh)
|
2000-05-19 |
2015-03-04 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
|
CN1592645A
(zh)
*
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
IL160127A0
(en)
*
|
2001-08-03 |
2004-06-20 |
Genentech Inc |
Tacis and br3 polypeptides and uses thereof
|
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
CA2492447A1
(en)
*
|
2002-07-25 |
2004-02-05 |
Genentech, Inc. |
Taci antibodies and uses thereof
|
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
AU2003262650B2
(en)
|
2002-08-14 |
2009-10-29 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
CN103833854B
(zh)
*
|
2002-12-16 |
2017-12-12 |
健泰科生物技术公司 |
免疫球蛋白变体及其用途
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
EP2368578A1
(de)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
|
NZ587776A
(en)
|
2003-04-09 |
2012-03-30 |
Genentech Inc |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
EP1629001A2
(de)
|
2003-06-05 |
2006-03-01 |
Genentech, Inc. |
Blys-antagonisten und deren verwendung
|
|
ATE402947T1
(de)
|
2003-06-25 |
2008-08-15 |
Peregrine Pharmaceuticals Inc |
Verfahren und vorrichtung zur kontinuierlichen radioaktiven markierung von proteinen im grossen massstab
|
|
ZA200600798B
(en)
*
|
2003-07-29 |
2007-06-27 |
Genentech Inc |
Assay for human anti CD20 antibodies and uses therefor
|
|
ZA200601218B
(en)
*
|
2003-08-29 |
2007-05-30 |
Genentech Inc |
Anti-CD20 therapy of ocular disorders
|
|
CA2549237A1
(en)
*
|
2003-12-19 |
2005-07-07 |
Genentech, Inc. |
Detection of cd20 in transplant rejection
|
|
JP2007514787A
(ja)
*
|
2003-12-19 |
2007-06-07 |
ジェネンテック・インコーポレーテッド |
自己免疫疾患の治療におけるcd20の検出
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US8883160B2
(en)
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
MXPA06011805A
(es)
*
|
2004-04-16 |
2006-12-15 |
Genentech Inc |
Metodo para aumentar agotamiento de celulas b.
|
|
BRPI0509412A
(pt)
*
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
|
|
BRPI0510224A
(pt)
*
|
2004-05-05 |
2007-10-23 |
Genentech Inc |
métodos de prevenção de doença autoimunológica e artigo industrializado
|
|
MXPA06012601A
(es)
|
2004-05-10 |
2007-05-10 |
Macrogenics Inc |
Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
|
|
US20060024295A1
(en)
*
|
2004-06-04 |
2006-02-02 |
Genentech, Inc. |
Method for treating lupus
|
|
TW201422238A
(zh)
*
|
2004-06-04 |
2014-06-16 |
Genentech Inc |
Cd20抗體於治療多發性硬化症之用途及用於該用途之物品
|
|
CA2573359A1
(en)
*
|
2004-07-22 |
2006-02-02 |
Genentech, Inc. |
Method of treating sjogren's syndrome
|
|
PL2213683T3
(pl)
|
2004-08-04 |
2013-10-31 |
Mentrik Biotech Llc |
WARIANTY REGIONÓW Fc
|
|
BRPI0516297A
(pt)
*
|
2004-10-05 |
2008-09-02 |
Genentech Inc |
métodos de tratamento de vasculite e artigos de fabricação
|
|
US7632497B2
(en)
|
2004-11-10 |
2009-12-15 |
Macrogenics, Inc. |
Engineering Fc Antibody regions to confer effector function
|
|
ZA200705459B
(en)
*
|
2005-01-13 |
2008-09-25 |
Genentech Inc |
Treatment method
|
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
US20060246975A1
(en)
*
|
2005-04-07 |
2006-11-02 |
Frank J. Pellegrini |
Character matching game
|
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
|
JP2008538767A
(ja)
*
|
2005-04-22 |
2008-11-06 |
ジェネンテック・インコーポレーテッド |
Cd20抗体による認知症又はアルツハイマー病の治療方法
|
|
MX2007014497A
(es)
*
|
2005-05-20 |
2008-02-07 |
Genentech Inc |
Pretratamiento de una muestra biologica de un sujeto con enfermedad autoinmune.
|
|
NZ565173A
(en)
|
2005-07-25 |
2012-01-12 |
Emergent Product Dev Seattle |
Single dose use of CD20 scFv for rheumatoid arthritis
|
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
SG155912A1
(en)
|
2005-07-25 |
2009-10-29 |
Trubion Pharmaceuticals Inc |
B-cell reduction using cd37-specific and cd20-specific binding molecules
|
|
SI2573114T1
(sl)
|
2005-08-10 |
2016-08-31 |
Macrogenics, Inc. |
Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
|
KR100693340B1
(ko)
|
2005-08-12 |
2007-03-09 |
삼성전자주식회사 |
화상 형성 장치
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
CA2629306A1
(en)
*
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
ES2489646T3
(es)
|
2006-05-26 |
2014-09-02 |
Macrogenics, Inc. |
Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
|
|
AU2007257692B2
(en)
|
2006-06-12 |
2013-11-14 |
Aptevo Research And Development Llc |
Single-chain multivalent binding proteins with effector function
|
|
LT2029173T
(lt)
|
2006-06-26 |
2016-11-10 |
Macrogenics, Inc. |
Fc riib specifiniai antikūnai ir jų panaudojimo būdai
|
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
|
US8557764B2
(en)
|
2007-01-26 |
2013-10-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Methods of modulating immune function
|
|
HUE061746T2
(hu)
|
2007-07-09 |
2023-08-28 |
Genentech Inc |
Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
|
|
ES2565202T3
(es)
|
2007-10-16 |
2016-04-01 |
Zymogenetics, Inc. |
Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
|
|
EP2077281A1
(de)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
|
|
US7914785B2
(en)
*
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
|
CA2720365C
(en)
|
2008-04-02 |
2019-01-15 |
Macrogenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
|
PT2132228E
(pt)
|
2008-04-11 |
2011-10-11 |
Emergent Product Dev Seattle |
Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
|
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
|
CA2743487A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Emergent Product Development Seattle, Llc |
Cd37 immunotherapeutic combination therapies and uses thereof
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
|
AU2010282733B2
(en)
|
2009-08-11 |
2016-07-14 |
Genentech, Inc. |
Production of proteins in glutamine-free cell culture media
|
|
CA2776385C
(en)
|
2009-10-07 |
2019-04-09 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
JP5841072B2
(ja)
|
2010-02-10 |
2016-01-06 |
イミュノジェン・インコーポレーテッド |
Cd20抗体およびその使用
|
|
LT2542256T
(lt)
|
2010-03-04 |
2019-10-25 |
Macrogenics Inc |
Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
EP2788020A4
(de)
|
2011-12-05 |
2015-04-29 |
Immunomedics Inc |
Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
CA3177936A1
(en)
|
2012-12-13 |
2014-06-19 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
ES2819573T3
(es)
|
2012-12-13 |
2021-04-16 |
Immunomedics Inc |
Método para producir inmunoconjugados de anticuerpo-SN-38 con un enlazador CL2A
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
US20240139324A1
(en)
|
2012-12-13 |
2024-05-02 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
CN106029098A
(zh)
|
2014-02-25 |
2016-10-12 |
免疫医疗公司 |
人源化rfb4抗cd22抗体
|
|
WO2016172427A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
RS60441B1
(sr)
|
2015-05-30 |
2020-07-31 |
Molecular Templates Inc |
De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
|
|
JP6691144B2
(ja)
|
2015-06-24 |
2020-04-28 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
目的に合わせた親和性を有する抗トランスフェリンレセプター抗体
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
EP3352760B1
(de)
|
2015-09-21 |
2026-03-11 |
Aptevo Research and Development LLC |
Cd3-bindende polypeptide
|
|
EP3356406A1
(de)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispezifische antikörper gegen menschliches cd20/gegen den menschlichen transferrinrezeptor und verfahren zur verwendung
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
US20170224837A1
(en)
|
2016-02-10 |
2017-08-10 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
|
PE20190353A1
(es)
|
2016-04-15 |
2019-03-07 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
|
|
RU2725292C2
(ru)
|
2016-04-27 |
2020-06-30 |
Иммьюномедикс, Инк. |
Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
|
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
|
CN110352201A
(zh)
|
2017-04-03 |
2019-10-18 |
免疫医疗公司 |
用于癌症疗法的抗体药物缀合物的皮下施用
|